Table 3. Multivariate analyses of potential prognostic factors for overall survival in patients undergoing neoadjuvant chemotherapy incorporating hCGβ level either before, or on completion of, chemotherapy.
| Factor | HR | 95% CI | P-value | HR | 95% CI | P-value |
|---|---|---|---|---|---|---|
|
ECOG PS | ||||||
| ⩾2 vs 0 or 1 |
2.10 |
0.41–10.89 |
0.38 |
2.14 |
0.31–14.95 |
0.44 |
|
Hb | ||||||
| <LLN vs ⩾LLN |
3.56 |
1.69–7.46 |
0.001 |
1.17 |
0.25–5.45 |
0.84 |
|
Chemotherapy regimen | ||||||
| GCarbo vs GC |
1.48 |
0.40–5.42 |
0.56 |
1.79 |
0.42–7.57 |
0.43 |
|
T stage | ||||||
| T3 vs T2 | 1.29 | 0.55–3.00 | 0.56 | 0.98 | 0.23–4.15 | 0.98 |
| T4 vs T2 |
1.76 |
0.47–6.61 |
0.40 |
0.66 |
0.07–6.04 |
0.71 |
|
hCGβ
level before chemotherapy | ||||||
| ⩾2 vs <2 |
3.41 |
1.49–7.83 |
0.004 |
— |
— |
— |
|
hCGβ
level on completion of chemotherapy | ||||||
| ⩾2 vs <2 | — | — | — | 15.36 | 2.13–110.7 | 0.007 |
Abbreviations: CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group performance status; GC=gemcitabine/cisplatin; GCarbo=gemcitabine/carboplatin; Hb=haemoglobin; HR=hazard ratio; LLN=lower limit of normal for the treating institution's reference range.